Edwards Lifesciences: Company Market Research Report

Company Overview

• Name: Edwards Lifesciences Corporation

• Mission: Driven by a passion to improve patient lives through innovative solutions for people fighting cardiovascular disease.

• Founding: The company was conceptualized in 1958 by Miles “Lowell” Edwards.

• Key People:

• Bernard Zovighian, CEO

• Mark Wilterding, SVP, Investor Relations

• Amy Hytowitz, VP, Global Communications

• Headquarters: Irving, California, USA

• Number of Employees: Over 16,000 globally

• Revenue: No information is available

• Known For: Leading global innovations in structural heart technologies, providing solutions through partnerships with clinicians and healthcare stakeholders.

Products

• Transcatheter Heart Valves:

• Description: Provides less invasive treatment options for heart valve diseases.

• Key Features: Minimally invasive procedure, shorter recovery time, viability for patients unsuitable for open-heart surgery.

• Transcatheter Mitral and Tricuspid Technologies:

• Description: Advanced solutions addressing mitral and tricuspid valve disorders.

• Key Features: Innovative designs for valve performance improvements, aimed at enhancing longevity and quality of life.

• Surgical Valve Technologies:

• Description: Traditional heart valve surgeries with advanced surgical products.

• Key Features: Proven durability and functionality, support for surgical valve replacements.

• Critical Care Technologies:

• Note: Edward Lifesciences' Critical Care division has been sold to BD (Becton, Dickinson, and Company).

Recent Developments

• Recent Developments:

• Completed the sale of its Critical Care product group to BD for $4.2 billion.

• Entered into a $500 million Accelerated Share Repurchase agreement.

• Announced an additional $1.5 billion share repurchase authorization, with $1.4 billion remaining for future repurchases.

• New Products Launched: No specific new products were mentioned.

• New Features Added to Existing Products: No information available related to features added.

• New Partnerships: No new partnerships were explicitly mentioned in the available information.

Corporate Impact and Giving

• Charitable Initiatives:

• The Edwards Lifesciences Foundation supports health- and community-focused programs globally.

• Aspires to improve the lives of 2.5 million more underserved patients by 2025 through "Every Heartbeat Matters."

• Offers an employee matching gift program to encourage charitable donations.

• Philanthropic Goals: Partnerships with global charities to grant funding and provide product donations for humanitarian purposes.

Conclusion

Edwards Lifesciences continues to reinforce its leadership position in structural heart disease technologies by focusing on innovative patient solutions and strengthening shareholder value through strategic sales and repurchase plans. The strong organizational commitment to philanthropy further highlights its dedication to global community health improvements.

For more information, visit [Edwards Lifesciences](http://www.edwards.com) or follow them on social media platforms such as LinkedIn, Facebook, Instagram, and YouTube.